1223593-73-4 Usage
Description
(E)-tert-butyl 2-(4-(3-(hydroxyaMino)-3-oxoprop-1-en-1-yl)benzoyl)hydrazinecarboxylate, also known as Rucaparib, is a chemical compound that belongs to the class of PARP inhibitors. It is characterized by its unique chemical structure that enables it to inhibit the activity of PARP enzymes, which are involved in the repair of damaged DNA in cancer cells. By blocking this repair process, Rucaparib leads to the accumulation of DNA damage and ultimately the death of cancer cells.
Uses
Used in Pharmaceutical Industry:
Rucaparib is used as an anticancer agent for the treatment of advanced ovarian cancer. It is particularly effective in patients who have received prior chemotherapy treatment and possess a specific genetic mutation known as BRCA. (E)-tert-butyl 2-(4-(3-(hydroxyaMino)-3-oxoprop-1-en-1-yl)benzoyl)hydrazinecarboxylate's ability to inhibit PARP enzymes and prevent DNA repair in cancer cells makes it a valuable option for patients with this type of cancer.
Used in Clinical Trials:
Rucaparib has been extensively studied in clinical trials, demonstrating promising results in the treatment of ovarian cancer. Its efficacy and safety have been evaluated in various stages of the disease, and it has shown significant improvements in progression-free survival and overall survival rates in patients with BRCA-mutated ovarian cancer.
Used in Combination Therapies:
Rucaparib is also being investigated for its potential use in combination with other cancer treatments, such as chemotherapy and immunotherapy. The synergistic effects of these combinations may enhance the overall efficacy of the treatment and provide additional options for patients with advanced ovarian cancer.
Used in Personalized Medicine:
The development and approval of Rucaparib highlight the growing importance of personalized medicine in cancer treatment. By targeting a specific genetic mutation (BRCA), Rucaparib offers a tailored treatment option for patients with this genetic profile, increasing the likelihood of a positive response to therapy and improving patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1223593-73-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,3,5,9 and 3 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1223593-73:
(9*1)+(8*2)+(7*2)+(6*3)+(5*5)+(4*9)+(3*3)+(2*7)+(1*3)=144
144 % 10 = 4
So 1223593-73-4 is a valid CAS Registry Number.
1223593-73-4Relevant articles and documents
CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF
-
Page/Page column 96, (2011/02/24)
HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and d
